Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.20.2
Segment Information (Tables)
9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Summary of Segment Information
The following table summarizes the segment information (in thousands):

Three Months Ended September 30, Nine Months Ended September 30,
2020 2019 2020 2019
Net revenues:
Clinical Services $ 108,733  $ 92,565  $ 275,599  $ 267,757 
Pharma Services 16,711  12,107  42,852  34,205 
Total revenue 125,444  104,672  318,451  301,962 
Cost of revenue:
Clinical Services 60,607  47,526  158,287  136,557 
Pharma Services 10,772  6,314  31,724  18,492 
Total cost of revenue 71,379  53,840  190,011  155,049 
Gross Profit:
Clinical Services 48,126  45,039  117,312  131,200 
Pharma Services 5,939  5,793  11,128  15,713 
Total gross profit 54,065  50,832  128,440  146,913 
Operating expenses:
General and administrative 36,128  33,054  107,085  94,773 
Research and development 1,964  2,611  6,129  6,407 
Sales and marketing 11,304  11,508  34,757  35,048 
Total operating expenses 49,396  47,173  147,971  136,228 
Income (loss) from operations 4,669  3,659  (19,531) 10,685 
Interest expense, net 2,458  203  4,825  3,333 
Other (income) expense, net (11) (35) (7,639) 5,124 
Loss on extinguishment of debt —  —  1,400  1,018 
Loss on termination of cash flow hedge —  —  3,506  — 
Income (loss) before taxes 2,222  3,491  (21,623) 1,210 
Income tax (benefit) expense (335) 1,348  (10,378) (500)
Net income (loss) $ 2,557  $ 2,143  $ (11,245) $ 1,710